SNY - Sanofi

-

$undefined

N/A

(N/A)

Sanofi NasdaqGS:SNY Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Location: 46, avenue de la Grande Armée, Paris, 75017, France | Website: https://www.sanofi.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

76.33B

Cash

7.556B

Avg Qtr Burn

N/A

Short % of Float

0.33%

Insider Ownership

0.00%

Institutional Own.

10.49%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Dupixent Details
Chronic obstructive pulmonary disease

Approved

Quarterly sales

Dupixent Details
Chronic spontaneous urticaria

Approved

Quarterly sales

Approved

Quarterly sales

Beyfortus™ (Nirsevimab- alip) Details
Respiratory syncytial virus

Approved

Quarterly sales

Dupixent Details
Eosinophilic Esophagitis

Approved

Quarterly sales

Approved

Quarterly sales

Dupixent Details
Chronic rhinosinusitis with nasal polyps

Approved

Quarterly sales

Sarclisa® Details
Multiple myeloma, Cancer

Approved

Quarterly sales

Tolebrutinib Details
Multiple sclerosis, Autoimmune disease

BLA

Submission

ExPEC9V vaccine Details
Invasive Extraintestinal Pathogenic Escherichia Coli Disease

Phase 3

Data readout

Amlitelimab Details
Atopic dermatitis

Phase 3

Data readout

Tzield (Teplizumab) Details
Type 1 diabetes, Diabetes

Phase 3

Update

Frexalimab Details
Autoimmune disease, Multiple sclerosis

Phase 3

Update

Ordesekimab (PRV-015) (anti-IL-15) Details
Celiac disease, Immune Disorders

Phase 2b

Data readout

INBRX-101 (AAT-Fc fusion protein) Details
Genetic disorder, Severe alpha-1 antitrypsin deficiency, Rare genetic disease, Emphysema due to Alpha-1 Antitrypsin Deficiency

Phase 2

Data readout

PRV-3279 Details
Systemic lupus erythematosus, Autoimmune disease

Phase 2a

Data readout